The purpose of this study is to determine the effect of periodontal therapy on endothelial function and other biomarkers of cardiovascular disease
Periodontitis is one of the most prevalent chronic diseases and a frequent cause of tooth loss. Accumulation of subgingival dental biofilm in susceptible individuals is associated with an inflammatory host response characterized by the production of Matrix Metalloproteinases, reduction in collagen synthesis, increase in cytokine gene expression, and apoptosis of gingival fibroblasts. Finally, inflammation leads to destruction of periodontal ligament, alveolar bone resorption, and chronic periodontitis. Periodontitis is associated with increased serum levels of inflammatory cytokines and acute phase reactants. Multiple case-control and cohort studies have suggested that periodontitis is an independent risk factor for cardiovascular events, diabetic end-organ damage, pregnancy complications and respiratory diseases. Recent interventional studies have found that periodontal therapy could increase endothelium-dependent brachial artery flow-mediated dilation. The purpose of this controlled clinical trial is to determine the effect of periodontal therapy on endothelial function in subjects with moderate to severe chronic periodontitis. Furthermore, the relationship between putative periodontal pathogens and endothelial function will be also evaluated.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
102
* Scaling and root planing, four quadrants in one session * Tongue brushing with a 1% chlorhexidine gel (1 minute) * Mouth rinsing with a 0.2% chlorhexidine solution for (2 minutes) * Subgingival chlorhexidine (1%) irrigation in all pockets * Twice daily rinsing with clorhexidine (1 minute) during fourteen days after the periodontal intervention * Basic oral hygiene instructions * Dental extractions will be performed at the end of patient followup (only in cases of teeth that could not be saved)
* Basic oral hygiene instructions * Supragingival plaque removal
Red de Salud de Ladera E.S.E. Servicio de Odontología
Cali, Valle del Cauca Department, Colombia
Universidad del Valle, Facultad de Salud, Escuela de Odontología
Cali, Valle del Cauca Department, Colombia
Brachial Artery Flow-mediated Dilation
All the assessments of vascular function were performed in the morning, in a temperature controlled room, with participants required to fast for at least 8 hours. Flow-mediated, endothelium dependent vasodilatation of the brachial artery (FMD) was measured using the technique described by Celermajer et al. using the guidelines reported by Coretti et al. FMD was calculated as the percentage of change in the diameter of brachial artery measured 45-60 s after cuff release in relation to the baseline measure (FMD%).
Time frame: Baseline; 24 hours post periodontal therapy; 12 weeks post periodontal therapy
High-sensitivity C-Reactive Protein
The fasting plasma hs-CRP concentrations was evaluated using a quantitative solid-phase, chemiluminescent immunometric assay (Immulite 1000, Siemens).
Time frame: Baseline; 24 hours post periodontal therapy; 12 weeks post periodontal therapy
Total Cholesterol
Time frame: Baseline; 24 hours post periodontal therapy; 12 weeks post periodontal therapy
White Blood Cell Count
Time frame: Baseline; 24 hours post periodontal therapy; 12 weeks post periodontal therapy
Subgingival Microbiota
Polymerase chain reaction (PCR) was used for detection of the three red-complex periodontal pathogens in periodontal pockets: Porphyromonas gingivalis (Pg), Treponema denticola (Td) and Tannerella forsythia (Tf).
Time frame: 12 weeks post-periodontal therapy
LDL Cholesterol
Time frame: Baseline; 24 hours post periodontal therapy; 12 weeks post periodontal therapy
Endothelial Leukocyte Adhesion Molecule-1 (E-Selectin)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Multiplexed immuno-cytometric assay for the simultaneous measurement of MMP-9, MPO, tPAI-1, E-Selectin, ICAM-1, and VCAM-1 in serum samples (Milliplex® MAP kit, Human Cardiovascular Disease Panel 1, Millipore®). Luminex® 200™ IS Total System and xPONENT software were used for data acquisition and analysis.
Time frame: 12 weeks post periodontal therapy
Intercellular Adhesion Molecule 1 (ICAM-1)
Time frame: 12 weeks post periodontal therapy
Vascular Cell Adhesion Molecule 1 (VCAM-1)
Time frame: 12 weeks post periodontal therapy
Myeloperoxidase (MPO)
Time frame: 12 weeks post periodontal therapy
Matrix Metalloproteinase-9 (MMP-9)
Time frame: 12 weeks post periodontal therapy
Tissue Plasminogen Activator Inhibitor-1 (tPAI-1)
Time frame: 12 weeks post periodontal therapy